Valuation: Exelixis, Inc.

Market Cap 1.27TCr 1.1TCr 1.03TCr 937.14Cr 1.76TCr 1,21400Cr 1.79TCr 12TCr 4.72TCr 61TCr 4.77TCr 4.66TCr 2,02000Cr P/E 2026 *
15.9x
P/E 2027 * 13.7x
Enterprise Value 1.2TCr 1.03TCr 970.02Cr 882.19Cr 1.66TCr 1,14300Cr 1.69TCr 11TCr 4.44TCr 57TCr 4.49TCr 4.39TCr 1,90200Cr EV / Sales 2026 *
4.68x
EV / Sales 2027 * 3.85x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+1.24%
1 week-5.23%
Current month-3.38%
1 month-8.12%
3 months+0.27%
6 months+16.67%
Current year+16.91%
1 week 49.97
Extreme 49.97
54.02
1 month 49.97
Extreme 49.97
56.95
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 10.04
Extreme 10.04
57.57
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Date Insider Type Main position Quantity % Market Cap.
10/08/26 Sell

Director

-9,812 0.0039%
27/05/26 Free

Director

8,367 0.0033%
26/02/26 Free

General Counsel

23,119 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
+1.24%-5.23%+33.19%+138.21% 1.25TCr
-1.90%+2.85%+61.37%+102.88% 7.16TCr
-3.21%-4.32%+31.19%+59.75% 5.44TCr
-2.05%-5.61%-3.14%+454.89% 2.76TCr
-1.27%-1.57%+46.46%+6.09% 2.39TCr
+1.05%-0.62%-17.40%-13.36% 2.31TCr
+0.10%+1.40%+38.98%-20.04% 1.87TCr
+3.81%+20.97%+263.48%+552.47% 1.86TCr
-0.95%-3.52%+20.04%+613.01% 1.6TCr
+0.04%-0.49%+36.67%+192.64% 1.17TCr
Average -0.31%+1.69%+51.09%+208.65% 2.78TCr
Weighted average by Cap. -1.08%+0.44%+48.59%+167.98%

Financials

2026 *2027 *
Net sales 255.17Cr 220.39Cr 207.1Cr 188.34Cr 354.1Cr 24TCr 359.94Cr 2.43TCr 948.76Cr 12TCr 958.03Cr 937.23Cr 41TCr 287.45Cr 248.27Cr 233.3Cr 212.18Cr 398.91Cr 27TCr 405.48Cr 2.73TCr 1.07TCr 14TCr 1.08TCr 1.06TCr 46TCr
Net income 81Cr 70Cr 66Cr 60Cr 113.03Cr 7.79TCr 114.89Cr 774.54Cr 302.84Cr 3.9TCr 305.8Cr 299.16Cr 13TCr 96Cr 83Cr 78Cr 71Cr 133.67Cr 9.21TCr 135.87Cr 916.01Cr 358.15Cr 4.61TCr 361.65Cr 353.79Cr 15TCr
Net Debt -74Cr -64Cr -60Cr -55Cr -103.31Cr -7.12TCr -105.02Cr -707.97Cr -276.81Cr -3.56TCr -279.51Cr -273.45Cr -12TCr -162.27Cr -140.15Cr -131.7Cr -119.77Cr -225.18Cr -16TCr -228.89Cr -1.54TCr -603.34Cr -7.77TCr -609.23Cr -596.01Cr -26TCr
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
14/26/14 $51.24 +1.24% 23,42,387
13/26/13 $50.61 +0.46% 19,48,740
12/26/12 $50.38 -1.85% 29,38,705
11/26/11 $51.33 -3.08% 20,38,685
10/26/10 $52.96 -2.05% 33,49,673
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
51.24USD
Average target price
52.94USD
Spread / Average Target
+3.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock